Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
Nusayba A. Bagegni(Washington University in St. Louis), X. Cynthia(Washington University in St. Louis)
Cited by 70
Related Papers
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
|Cell Reports|2013|630
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
|Journal of Clinical Oncology|2017|411
NCCN Guidelines Insights: Antiemesis, Version 2.2017
|Journal of the National Comprehensive Cancer Network|2017|250
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
|Journal of Clinical Investigation|2012|222
Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer
|Clinical Cancer Research|2017|191